MASCT is under clinical development by HRYZ (ShenZhen) Biotech and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData, Phase I drugs for Bile Duct Cancer (Cholangiocarcinoma) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MASCT’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cellular immunotherapy is under development for the treatment of soft tissue sarcoma, bladder cancer, osteosarcoma, pancreatic cancer, nasopharyngeal cancer, urothelial cell carcinoma, bile duct cancer (cholangiocarcinoma) and urethral cancer. It is administered as intravenous drip. The therapeutic candidate constitutes autologous dendritic cells loaded with antigens called as multiple antigens specific cellular therapy (MASCT). It was also under development for hepatocellular carcinoma, gastric cancer, gastroesophageal adenocarcinoma, triple-negative breast cancer, ovarian cancer, adenocarcinoma of the gastroesophageal junction, advanced solid tumors including lung cancer, colon cancer, prostate cancer,
For a complete picture of MASCT’s drug-specific PTSR and LoA scores, buy the report here.